Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $65.1 million.

  • Vistagen Therapeutics' Liabilities and Shareholders Equity fell 2952.21% to $65.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $299.2 million, marking a year-over-year decrease of 3072.98%. This contributed to the annual value of $84.3 million for FY2025, which is 3179.22% down from last year.
  • According to the latest figures from Q4 2025, Vistagen Therapeutics' Liabilities and Shareholders Equity is $65.1 million, which was down 2952.21% from $80.9 million recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' Liabilities and Shareholders Equity ranged from a high of $131.1 million in Q4 2023 and a low of $15.0 million during Q2 2023
  • Over the past 5 years, Vistagen Therapeutics' median Liabilities and Shareholders Equity value was $82.6 million (recorded in 2025), while the average stood at $77.4 million.
  • Per our database at Business Quant, Vistagen Therapeutics' Liabilities and Shareholders Equity soared by 177587.79% in 2021 and then tumbled by 7440.25% in 2023.
  • Vistagen Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $90.5 million in 2021, then tumbled by 67.19% to $29.7 million in 2022, then surged by 341.18% to $131.1 million in 2023, then fell by 29.57% to $92.3 million in 2024, then fell by 29.52% to $65.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $65.1 million in Q4 2025, compared to $80.9 million in Q3 2025 and $68.9 million in Q2 2025.